Gilead's PrEP Research Deal With CDC Is Factor In Outcome Of HIV Patent Suit

 
• By Brenda Sandburg

Patent board won't review IPR petitions challenging HHS patents, but Gilead says it has additional defenses against government's infringement suit, including a breach of contract claim.

PrEP on the touch screen with medicine icons on the background blur Doctor in hospital.Innovation treatment, service, data analysis health. Medical Healthcare Concept Pre-Exposure Prophylaxis
Gilead says government patents covering HIV pre-exposure prophylaxis drugs are invalid and unenforceable.

More from Legal & IP

More from Pink Sheet